Weight
Mazdutide
Metabolic
31
Amino acids
Molecular weight
Peptide
Type
Mazdutide (IBI362; brand name Xinermei) is a synthetic analog of oxyntomodulin and a dual agonist of the GLP-1 receptor and glucagon receptor, developed by Innovent Biologics and Eli Lilly. It reduces body weight through appetite suppression and increased energy expenditure, and improves glycemic control in type 2 diabetes. Mazdutide received NMPA approval in China in June 2025 for chronic weight management and in September 2025 for type 2 diabetes; it is not FDA-approved and remains investigational outside China.
Top researched benefits
Overview of Mazdutide
Mazdutide co-activates the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), reducing appetite and slowing gastric emptying via GLP-1R signaling while increasing energy expenditure and hepatic fatty acid oxidation through GCGR-mediated thermogenesis. It also modulates the PERK-eIF2α-ATF4-CHOP endoplasmic reticulum stress pathway to improve hepatic lipid metabolism and alleviate hepatic inflammation.
weight loss
- GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
- Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
- Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.
type 2 diabetes
- HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
- 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.
cardiovascular
- Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
- Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.
Typical Dose
4–6 mg per injection (titrated from 2–3 mg starting dose)
Frequency
once weekly subcutaneous injection
Cycle Duration
48 weeks in Phase 3 trials; titrated upward over 8–12 weeks
Storage
Lyophilized: -20°C for up to 1 year or -80°C for up to 2 years, sealed away from moisture and light. Reconstituted: refrigerate at 2–8°C; avoid freeze-thaw cycles.
Chemical Makeup
Key benefits
Produces 11–21% mean body weight reduction over 24–48 weeks in overweight and obese adults in Phase 2 and 3 trials
Improves HbA1c and glycemic control in type 2 diabetes, outperforming semaglutide in head-to-head DREAMS-3 Phase 3 trial
Reduces waist circumference and visceral fat through combined GLP-1R appetite suppression and GCGR-driven energy expenditure
Resolves hepatic steatosis in over 60–70% of patients with MASLD and baseline liver fat content ≥5%, with mean liver fat reductions of up to 68.8% versus -14.1% for placebo at 32 weeks
Community interest
This peptide is still gaining traction in the community.
GLP-1R/GCGR Dual Agonist | Obesity & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoMazdutide Molecular Information
View the scientifc details of Mazdutide.
31
Amino Acids
Mazdutide
Ala
Ala
Position 1
Met
Met
Position 2
Ile
Ile
Position 3
Asn
Asn
Position 4
Pyl
Pyl
Position 5
Ala
Ala
Position 6
Cys
Cys
Position 7
Ile
Ile
Position 8
Asp
Asp
Position 9
Leu
Leu
Position 10
Ile
Ile
Position 11
Asn
Asn
Position 12
Glu
Glu
Position 13
Ala
Ala
Position 14
Arg
Arg
Position 15
Ser
Ser
Position 16
Tyr
Tyr
Position 17
Asn
Asn
Position 18
Thr
Thr
Position 19
His
His
Position 20
Glu
Glu
Position 21
Thr
Thr
Position 22
Ile
Ile
Position 23
Cys
Cys
Position 24
Pro
Pro
Position 25
Glu
Glu
Position 26
Pro
Pro
Position 27
Thr
Thr
Position 28
Ile
Ile
Position 29
Asp
Asp
Position 30
Glu
Glu
Position 31
Molecular Weight
4563.14DaChain Length
31Amino AcidsType
PeptideMazdutide Protocols
Subcutaneous injection is the only documented route for Mazdutide, a dual GLP-1/glucagon receptor agonist used for weight management and metabolic disease. Administered once weekly into the abdomen, thigh, or upper arm, with systematic site rotation to prevent lipodystrophy.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Weight loss (moderate dose) | 6 | 1 week range | SubQ |
| Weight loss (low maintenance) | 4 | 1 week range | SubQ |
| Weight loss (high dose) | 9 | 1 week range | SubQ |
| Type 2 diabetes and obesity | 6 | 1 week range | SubQ |
| Metabolic-associated steatotic liver disease (MASLD) | 10 | 1 week range | SubQ |
| Dose titration start (standard) | 3 | 1 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Allow the Mazdutide vial (lyophilized powder) to reach room temperature for 10–15 minutes before reconstitution
- Draw 3.0 mL of bacteriostatic water into a sterile syringe
- Insert the needle through the vial stopper and inject the bacteriostatic water slowly down the inner wall of the vial — not directly onto the powder
- Gently swirl the vial in a circular motion until the powder is fully dissolved — do not shake or vortex
- Inspect the solution — it should be clear and colorless; discard if cloudy, discolored, or particulates are visible
- Label the vial with the reconstitution date; store at 2–8°C (refrigerator) and use within 28 days
- Clean the injection site with an alcohol swab and allow to air-dry completely before injecting
- Pinch a skin fold at the chosen site and insert the insulin syringe needle at a 45–90° angle into subcutaneous tissue
- Inject slowly and steadily over 5–10 seconds; do not aspirate
- Rotate injection sites weekly across the abdomen (at least 2 inches from the navel), front/outer thighs, or outer upper arms
Mazdutide Cycle
The Mazdutide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Appetite reduction, possible mild nausea, decreased portion sizes
- Week 3-4
- Early weight loss begins (1-2%), improved satiety after meals
- Week 4-8
- Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
- Week 8-16
- Steady weight loss continues (7-12%), energy expenditure effects evident
- Week 16-32
- Significant weight reduction (12-17%), metabolic markers improving
- Week 32-60
- Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose
Dosing tools
Mazdutide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Mazdutide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Mazdutide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Mazdutide
- Dosing
- 4–6 mg per injection (titrated from 2–3 mg starting dose)
- Dosing Frequency
- once weekly subcutaneous injection
- Cycle Duration
- 48 weeks in Phase 3 trials; titrated upward over 8–12 weeks
- Storage
- Lyophilized: -20°C for up to 1 year or -80°C for up to 2 years, sealed away from moisture and light. Reconstituted: refrigerate at 2–8°C; avoid freeze-thaw cycles.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Mazdutide interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions; may support gut health and potentially reduce GI side effects.
Weight
GLP-1
Metabolic
GLP-1
AVOID
Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
Side effects
Avoid: Do not take Mazdutide with GLP-1.
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Stop signs
Severe or persistent abdominal pain (potential pancreatitis)
Neck lumps, hoarseness, or difficulty swallowing
Severe nausea/vomiting preventing adequate nutrition or hydration
Signs of severe hypoglycemia (confusion, sweating, shakiness)
Severe allergic reactions (rash, difficulty breathing, facial swelling)
Unusual mood changes, depression, or suicidal thoughts
Signs of gallbladder problems (severe upper right abdominal pain)
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
MazdutideResearch References
Mazdutide is an approved compound
Mazdutide
Mazdutide is an approved compound
GLORY-1 Phase 3 Trial
610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.
2025
GLORY-2 Phase 3 Trial
462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.
2025
DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide
349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).
2025
Phase 2 T2D Trial
Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.
2024
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
